Tilray Q2 revenue rises, helped by international medical cannabis sales growth

Overview

• The cannabis maker's Q2 revenue rose 3% to $217.5 mln

• Adjusted net loss for Q2 improved slightly compared to last year

• Company holds $292 mln in cash and marketable securities

Outlook

• Tilray expects U.S. federal cannabis rescheduling to unlock new market opportunities

• Company plans to leverage existing infrastructure for U.S. medical cannabis expansion

• Tilray reaffirms fiscal 2026 Adjusted EBITDA guidance at $62 mln – $72 mln

Result Drivers

• INTERNATIONAL CANNABIS GROWTH - International medical cannabis revenue increased by 36%, contributing to overall cannabis revenue growth

• DISTRIBUTION SEGMENT - Distribution net revenue reached a record high of $85.3 million, up from $67.6 million

• BEVERAGE REVENUE DECLINE - Beverage net revenue decreased to $50.1 million from $63.1 million, impacting overall revenue growth

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Tilray Brands Inc is C$13.60, about 9.2% above its January 7 closing price of C$12.45

Press Release: ID:nGNXCLswC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.